XNAS
HYFT
Market cap67mUSD
Jul 09, Last price
1.46USD
1D
1.39%
1Q
36.45%
Name
Immunoprecise Antibodies Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
19.62%
Rev. gr., 5y
11.77%
Revenues
25m
+0.01%
Net income
-30m
L+15.77%
CFO
-6m
L+50.97%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ImmunoPrecise Antibodies Ltd. (IPA) is a global biotechnology firm that, through its subsidiaries, focuses on the development and production of antibodies, alongside offering a broad spectrum of related scientific services. Its operational footprint spans across the United States, Canada, Europe, Australia, and other international territories. For the research community, IPA delivers a diverse portfolio of products, including various types of antibodies, enzymes, enzyme activity assays, specialized animal products for arthritis studies, proteins (such as deiminated proteins), organoid growth factors, and hybridoma reagents. As a comprehensive Contract Research Organization (CRO), IPA provides an extensive suite of services covering the entire antibody discovery and development pipeline. This includes customized antigen design, modeling, and manufacturing; advanced B cell analysis encompassing sorting, screening, and sequencing; the development and screening of custom, immune, and naive phage display libraries; multi-species antibody discovery, including from transgenic animals; and the creation of specialized antibody formats such as bi-specific, tri-specific, VHH, and VNAR (shark) antibodies. Further expertise lies in DNA cloning, protein and antibody downstream processing, label-free biosensor-based antibody characterization, and antibody engineering. They also provide transient and stable cell line generation, antibody optimization and humanization, high-throughput hybridoma production with multiplexed screening and clone selection, and cryopreservation services. The company actively engages in strategic research collaborations, notably partnering with Pierre Fabre S.A. for antibody discovery initiatives. Additionally, it collaborates with Elektrofi, Inc. to investigate a high-concentration formulation for its COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was established in 1983 and maintains its headquarters in Victoria, Canada.
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑04 | 2024‑04 | 2023‑04 | 2022‑04 | 2021‑04 | 2020‑04 | 2019‑04 | 2018‑04 | 2017‑04 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT |